Ventyx Biosciences, Inc. (VTYX)
Mar 4, 2026 - VTYX was delisted (reason: acquired by LLY)
14.00
+0.02 (0.14%)
Inactive · Last trade price on Mar 3, 2026
Ventyx Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Ventyx Biosciences stock had an average target of 13.5, with a low estimate of 11 and a high estimate of 14.
Price Target: $13.5 (-3.57%)
Analyst Consensus: Hold
* Price targets were last updated on Jan 8, 2026.
Analyst Ratings
The average analyst rating for Ventyx Biosciences stock from 7 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 1 | 1 | 1 |
| Buy | 1 | 2 | 2 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 5 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 8, 2026 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 | Buy → Hold | Downgrades | $14 | n/a | Jan 8, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $14 | Strong Buy → Hold | Downgrades | $14 | n/a | Jan 8, 2026 |
| UBS | UBS | Strong Buy → Hold Downgrades $20 → $14 | Strong Buy → Hold | Downgrades | $20 → $14 | n/a | Jan 8, 2026 |
| LifeSci Capital | LifeSci Capital | Buy → Hold Downgrades $14 | Buy → Hold | Downgrades | $14 | n/a | Jan 8, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.48
from -1.97
EPS Next Year
-1.74
from -1.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.42 | -1.20 | ||||
| Avg | -1.48 | -1.74 | ||||
| Low | -1.54 | -2.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.